meta_pixel
Tapesearch Logo
Log in
Business Daily

The worldwide weight-loss revolution

Business Daily

BBC

Business

4.4816 Ratings

🗓️ 3 March 2026

⏱️ 18 minutes

🧾️ Download transcript

Summary

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value for money, and yet rollout is being phased in slowly because of cost and capacity pressures. In the United Arab Emirates, most patients rely on private insurance or pay out of their own pockets. And in India, where obesity is rising fast, affordability remains a major barrier, although lower-cost generics may soon change that. If these medicines can prevent diabetes, heart attacks and strokes, they might save health systems money in the long run. But right now, governments, insurers and patients are grappling with the same question: Can we afford the weight-loss revolution?

Produced and presented by Sam Fenwick

If you’d like to get in touch with the team, our email address is businessdaily@bbc.co.uk

Business Daily is the home of in-depth audio journalism devoted to the world of money and work. From small start-up stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.

Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.

Recent episodes explore the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.

We also feature in-depth interviews with company founders and some of the world's most prominent CEOs. These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.

(Photo: A man gets his waist measured. Credit: Getty Images)

Transcript

Click on a timestamp to play from that location

0:00.0

BBC Sounds, Music, Radio, podcasts.

0:07.0

Hello and welcome to Business Daily from the BBC World Service. I'm Sam Fennick.

0:13.1

Yesterday, we heard fears that a two-tier healthcare system is emerging in the United States,

0:19.4

splitting access to obesity drugs between those who can

0:23.0

afford to pay privately and those who can't.

0:26.4

Today, in the second part of our three-part series, looking at the global weight loss economy,

0:31.6

we're asking, if these drugs offer value for money around the world, who is paying for them. Most of the sales for these

0:39.1

drugs currently are accounted for by the upper socio-economic stratum. We are having stiff resistance

0:46.0

from the health insurance side because they don't want their budget to blow. If everyone would come

0:50.8

forward in the first year of it being available, if it take up, I think, something like 18% of the total primary care services.

1:00.9

We'll look at how obesity drugs are paid for in publicly funded health systems,

1:06.2

in one of the richest countries in the world,

1:08.3

and in the world's most populous country,

1:11.1

where obesity is rising fast and the ability to pay is far more limited.

1:23.1

So here we are running across the River Thames on Millennium Bridge

1:28.6

in the city of London.

1:31.7

It's a bit of a murky day.

1:34.0

Even the top of the shard is covered in cloud.

1:37.8

And my running partner today is Claire Barrett,

1:41.8

consumer editor and Financial Times journalist.

1:46.2

Now, about 12 months ago, would you have been doing this?

1:51.5

Well, the thoughts would have been there,

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from BBC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of BBC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.